Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody) | Zendy

A. Dupuy | Zendy; M. Viguier | Zendy; Christophe Bédane | Zendy; F. Cordoliani | Zendy; S. Blaise | Zendy; Françoise Aucouturier | Zendy; Jean-Marie Bonnetblanc | Zendy; Patrice Morel | Zendy; Louis Dubertret | Zendy; H. Bachelez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody)

Author(s) -

A. Dupuy,

M. Viguier,

Christophe Bédane,

F. Cordoliani,

S. Blaise,

Françoise Aucouturier,

Jean-Marie Bonnetblanc,

Patrice Morel,

Louis Dubertret,

H. Bachelez

Publication year - 2004

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archderm.140.1.91

Subject(s) - rituximab , medicine , refractory (planetary science) , pemphigus vulgaris , cd20 , immunology , monoclonal , autoantibody , monoclonal antibody , antibody , adjuvant , gastroenterology , physics , astrobiology

Pemphigus vulgaris (PV) is a severe antibody-mediated autoimmune blistering disease. Because some patients with PV do not enter into remission, despite the use of high-dose corticosteroid therapy and immunosuppressive adjuvant treatments, new effective and safer agents are warranted to treat refractory PV. Rituximab, a monoclonal anti-CD20 antibody, induces depletion of B cells in vivo and has shown efficacy in patients with refractory antibody-mediated autoimmune disorders. We describe herein 3 patients treated with rituximab for severe PV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research